Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$536.82M+215%
Amgen logo
AmgenAMGN
——
Biogen logo
BiogenBIIB
——
Royalty Pharma logo
Royalty PharmaRPRX
——
ResMed logo
ResMedRMD
——
Summit Therapeutics logo
Summit TherapeuticsSMMT
——

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation?
Jazz Pharmaceuticals (JAZZ) reported cash provided by (used in) investing activity, including discontinued operation of $123.1M in Q1 2026.
How has Jazz Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
Jazz Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation increased by 172.8% year-over-year, from -$169M to $123.1M.
What is the long-term trend for Jazz Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation?
Over 2 years (2021 to 2025), Jazz Pharmaceuticals's cash provided by (used in) investing activity, including discontinued operation has grown at a -46.2% compound annual growth rate (CAGR), from -$5.21B to -$1.51B.
What does cash provided by (used in) investing activity, including discontinued operation mean?
Net cash spent on or generated from investments.
How do you interpret cash provided by (used in) investing activity, including discontinued operation?
Negative values typically indicate active investment in growth, while positive values may indicate divestment or the maturity of investment portfolios.
How does cash provided by (used in) investing activity, including discontinued operation compare across companies?
Standard cash flow statement metric used to assess capital intensity.